Novel head frame designed for greater patient comfort and improved clinical
MADRID, September 28, 2016 – Elekta (EKTA-B.ST) introduces Leksell® Vantage™
Stereotactic System, its latest system for very precise neurosurgery, at the
European Society for Stereotactic and Functional Neurosurgery (ESSFN) meeting,
September 28 – October 1, in Madrid.
Based on the Leksell Stereotactic System®, which is considered the gold standard
within stereotactic neurosurgery, Leksell Vantage addresses the limitations of
using metal components during stereotactic MR and CT imaging. Constructed of a
novel epoxy composite, the robust, metal-free head frame design may allow for
faster and better stereotactic imaging. This means higher resolution MR imaging
of the brain and fewer artifacts introduced in stereotactic CT scanning.
Dee Mathieson, Senior Vice President, Treatment Management Portfolio, says:
“Building on our heritage and the invention of Lars Leksell, Elekta’s founder,
our current Leksell Stereotactic Systems have been employed in more than 1,500
centers worldwide. We expect the benefits of Leksell Vantage to make our system
even more competitive as it allows for faster stereotactic neuroimaging without
compromise, and with fewer components it results in a smoother workflow.”
Also important to clinicians is the new stereotactic arc, a surgical positioning
device which enables a faster preparation of the sterile field. Target
coordinates are easily set between the left and the right brain hemisphere in
deep brain stimulation (DBS) lead placements.
Leksell Vantage’s lightweight, open face design is created to improve the
patient experience. In addition to making it easier to eat or drink while the
frame is on, it has the potential to reduce MR scanning times. It essentially
eliminates the risk of device-related skin sensations due to temperature
increase during MR scans.
Stereotactic neurosurgery is a specialty often used for DBS implantations, brain
biopsies, drug deliveries to delicate brain targets, as well as cranial
radiosurgery. Leksell Vantage Stereotactic System is expected to be available
for clinical use in Europe during 2017.
The Leksell Vantage head frame is designed to be compatible with Leksell Gamma
Knife® Icon™ in a future release.
Leksell® Vantage™ Stereotactic System is not yet CE marked or 510(k) cleared and
is not available for sale or distribution.
# # #
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: email@example.com
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: firstname.lastname@example.org
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on September 28, 2016.
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,600 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.GlobeNewswireglobenewswire.com
Last updated on: 28/09/2016